Decibel Therapeutics rakes in $55 mln Series C
Boston-based Decibel Therapeutics, a developer of treatments for hearing loss and hearing-related disorders, has raised $55 million in Series C financing. The investors included Third Rock Ventures, GV, SR One, Regeneron Pharmaceuticals, Foresite Capital, Bessemer Venture Partners, Schroder Adveq, S-Cubed and Longevity.
19 June 2018•1 min read
